[Inner Mongolia Food and Drug Administration: Starting from October 12, risk control measures will be taken against Yuanhe Pharmaceutical to suspend the production and sales of pharyngitis lozenges] On October 12, the Inner Mongolia Autonomous Region Food and Drug Administration issued a notice on taking risk control measures. Recently, a reasoned inspection was carried out on Yuanhe Pharmaceutical Co., Ltd., and the comprehensive assessment concluded that it "does not meet the requirements." In order to prevent and control drug quality and safety risks, in accordance with the provisions of Paragraph 3 of Article 99 of the Drug Administration Law of the People's Republic of China, Paragraph 1 of Article 59 of the Measures for Supervision and Administration of Drug Production, and Paragraph 3 of Article 61 of the Measures for Drug Inspection and Administration (Trial), it was decided to take risk control measures to suspend the production and sale of pharyngitis lozenges for Yuanhe Pharmaceutical Co., Ltd. starting from October 12, 2026.